Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction

QR Code

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction

Aim. To study the levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with acute myocardial infarction (MI).Material and methods. The study included 74 patients with acute MI. PCSK9 was determined by enzyme-linked immunosorbent assay.Results. The mean PCSK9 levels were 479,7±...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. D. Gimadeeva, A. S. Galyavich, Z. M. Galeeva, L. V. Baleeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-03-01
Series:	Российский кардиологический журнал
Subjects:	proprotein convertase subtilisin/kexin type 9 myocardial infarction
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3724
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
by: Michał Majewski, et al.
Published: (2025-05-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

Human PCSK9D374Y exacerbates methionine choline deficiency diet-induced nonalcoholic steatohepatitis in mice
by: Abidan·ABUDURUSULI, CHEN Xiaocui, CUI Yuanfeng, Tuoluonayi·MIJITI, DENG Lihui, CHEN Bangdang
Published: (2025-05-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease
by: Angelika Hettenbach, et al.
Published: (2025-03-01)

Effect of immobilized hyaluronidase and subtilisin enzymes on the ultrastructure of human conjunctival epithelial cells
by: V. E. Zabanova, et al.
Published: (2023-02-01)

Chronotropic action of immobilized subtilisins during the perfusion of an isolated rat heart
by: G. I. Baikalov, et al.
Published: (2022-10-01)

Vasospastic angina — vasospastic myocardial infarction
by: A. S. Galyavich, et al.
Published: (2020-03-01)

Overproduction of Tk-Subtilisin and Elucidation of Its Structural Thermostability Based on Molecular Dynamics Studies
by: Nouman Rasool, et al.
Published: (2025-07-01)

SUB6 Subtilisin is Involved During the Initial Adhesion of Trichophyton benhamiae and T. mentagrophytes onto Reconstructed Human Epidermis
by: Émilie Faway, et al.
Published: (2025-07-01)

Gene Expression of Subtilisin Genes of UV-irradiated Trichophyton indotineae Isolated from Iraqi Patients
by: Aseel H. Hendi, et al.
Published: (2025-07-01)

Production of subtilisin proteases in bacteria and yeast
by: A. S. Rozanov, et al.
Published: (2021-03-01)

Regenerative effects of immobilized hyaluronidase and subtilisin enzymes on experimental models of chemical and mechanical corneal trauma
by: V. E. Zabanova, et al.
Published: (2023-12-01)

Myocardial infarction and Turner syndrome
by: A. S. Galyavich, et al.
Published: (2019-04-01)

Safety evaluation of the food enzyme subtilisin from the genetically modified Bacillus licheniformis strain NZYM‐CB
by: EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP), et al.
Published: (2024-04-01)

Predictive value of growth differentiation factor-15 in patients with myocardial infarction
by: A. A. Sabirzyanova, et al.
Published: (2021-03-01)

Growth differentiation factor-15 — a new indicator of unfavorable prognosis in uncomplicated myocardial infarction
by: A. S. Sabirzyanova, et al.
Published: (2023-09-01)

Safety evaluation of the food enzyme subtilisin from the non‐genetically modified Bacillus paralicheniformis strain AP‐01
by: EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP), et al.
Published: (2024-07-01)

THE VALUES OF MATRIX METALLOPROTEASE-9 AND TISSUE METALLOPROTEASE INHIBITOR-1 IN ACUTE MYOCARDIAL INFARCTION WITH ANEURYSM FORMATION
by: A. V. Govorin, et al.
Published: (2014-07-01)

MYOCARDIAL INFARCTION AND HEMOPHILIA
by: A. S. Galyavich, et al.
Published: (2016-03-01)

Matrix metalloprotease 9 and remodeling after myocardial infarction
by: M. G. Shurygin, et al.
Published: (2013-04-01)

PREDICTIVE ROLE OF CHROMOSOME 9P21.3 POLYMORPHISMS AND THEIR ASSOCIATION WITH FAMILY HISTORY OF CORONARY HEART DISEASE IN PATIENTS WITH MYOCARDIAL INFARCTION
by: P. A. Shesternya, et al.
Published: (2012-12-01)

REGIONAL ALGORITHM OF CARE IN ST ELEVATION MYOCARDIAL INFARCTION
by: A. Yu. Vafin, et al.
Published: (2016-03-01)

QUANTUM-CHEMICAL ANALYSIS OF THE ACTIVE SITE OF SUBTILISIN AND IMPROVING THE EFFICIENCY OF ENZYMATIC CATALYSIS IN FOOD TECHNOLOGY
by: Aleksandr Borisenko, et al.
Published: (2022-05-01)

Data on the care and prognosis of patients treated for myocardial infarction. Hungarian Myocardial Infarction Registry 2024
by: András Jánosi
Published: (2025-07-01)

Long-term mortality risk in hospitalized patients with heart failure after myocardial infarction
by: A. S. Galyavich, et al.
Published: (2020-02-01)

EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
by: E. I. Makhiyanova, et al.
Published: (2016-01-01)

THROMBOLYTIC THERAPY IN PATIENTS WITH MYOCARDIAL INFARCTION
by: G. P. Ishmurzin, et al.
Published: (2010-12-01)

MYCOPLASMA SPP. INFECTIONS AND MYOCARDIAL INFARCTION
by: I. P. Arleyevsky, et al.
Published: (2003-08-01)

Therapeutic hypothermia in acute myocardial infarction
by: V. V Ryabov, et al.
Published: (2023-08-01)

SIGNIFICANCE OF COPEPTIN IN DIAGNOSTICS OF MYOCARDIAL INFARCTION
by: L. V. Kremneva
Published: (2017-12-01)

IMPACT OF LOCUS 9P21.3 SINGLE NUCLEOTIDE POLYMORPHISMS ON CORONARY ATHEROSCLEROSIS SEVERITY AND LONG-TERM OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENT WITH MYOCARDIAL INFARCTION
by: P. A. Shesternya, et al.
Published: (2015-09-01)

Clinical outcomes in hypertension patients after coronary stenting due to exertional angina
by: R. N. Akhtereyev, et al.
Published: (2020-04-01)

Echocardiographic Diagnostics of Myocardial Infarction in Newborns
by: G. V. Revunenkov, et al.
Published: (2015-10-01)

Topical issues of myocardial infarction incidence statistics
by: E. P. Kakorina, et al.
Published: (2024-10-01)